Market Closed

LPCN
Lipocine
$ 1.71
5.56%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated 2 days ago

Lipocine News

Latest Lipocine Stock News & LPCN Headlines

Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
6 days ago | prnewswire.com
Lipocine Announces Financial Results for the Third Quarter of 2026
11 days ago | prnewswire.com
Here's Why You Should Add LPCN Stock to Your Portfolio Now
a month ago | zacks.com
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
a month ago | benzinga.com
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
a month ago | prnewswire.com
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
2 months ago | zacks.com
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
2 months ago | prnewswire.com
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2 months ago | prnewswire.com
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
3 months ago | prnewswire.com
Lipocine Appoints Michael J. Grissinger to Board of Directors
3 months ago | prnewswire.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

LPCN
Lipocine
$ 1.71
5.56%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated 2 days ago